E2 Secures Dual FDA Clearances for Hēlo Pulmonary Thrombectomy and Blood Return Systems

Endovascular Engineering (E2) has received dual FDA 510(k) clearances for its Hēlo® Thrombectomy System and Hēlo® Return, introducing an integrated platform designed to remove blood clots from pulmonary arteries and support blood conservation during treatment.

The Hēlo Thrombectomy System uses a steerable catheter with a 15F crossing profile to navigate the pulmonary vasculature. A 24F distal clot-ingestion funnel helps capture larger clots for removal.

The system combines continuous vacuum aspiration with mechanical clot disruption to capture and remove thrombi. This dual-action mechanism is designed to support effective clot removal while limiting blood loss.

Hēlo Return completes the platform by collecting and filtering whole blood aspirated during thrombectomy before returning it to the patient. The system is designed to reduce blood loss and integrate blood recovery into the procedural workflow.

The technology was evaluated in the ENGULF investigational device exemption (IDE) study, which assessed its safety and effectiveness in patients with pulmonary embolism.

Among patients treated with integrated blood return, the study reported near-zero estimated blood loss. The platform also demonstrated effective clot reduction and the potential for single-pass procedures. These capabilities could support pulmonary embolism treatment by combining clot removal and blood conservation within a single procedural system.